CYP2D6 genotyping for psychiatric patients treated with risperidone: Considerations for cost-effectiveness studies

Pharmacogenomics

Volumn 10, Issue 4, 2009, Pages 685-699

  Rodríguez Antona, Cristina ^a   Gurwitz, David ^b   de Leon, Jose ^c   Llerena, Adrián ^d   Kirchheiner, Julia ^e   de Mesa, Emma Gutiérrez ^f   Ibarreta, Dolores ^f  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF EXTREMADURA   (Spain)

^e UNIVERSITY OF ULM   (Germany)

^f JOINT RESEARCH CENTRE   (Italy)

Author keywords

Adverse drug reactions; Antipsychotic; Cost effectiveness; CYP2D6; Polymorphisms; Risperidone

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CYTOCHROME P450 2D6; FLUOXETINE; HALOPERIDOL; MIRTAZAPINE; NEUROLEPTIC AGENT; PALIPERIDONE; PAROXETINE; PHENOTHIAZINE; RIFAMPICIN; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; AUTONOMIC DYSFUNCTION; BIPOLAR MANIA; CASE STUDY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSFORMATION; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSTONIA; ENZYME ACTIVITY; ETHNIC DIFFERENCE; EUROPE; EXTRAPYRAMIDAL SYMPTOM; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; GILLES DE LA TOURETTE SYNDROME; HEALTH CARE COST; HEART DISEASE; HUMAN; LOW DRUG DOSE; MENTAL PATIENT; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPATHIC PAIN; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PERSONALITY DISORDER; PHARMACOGENETICS; PHENOTYPIC VARIATION; POSTTRAUMATIC STRESS DISORDER; PSYCHOSIS; QT PROLONGATION; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; TARDIVE DYSKINESIA; UNITED STATES; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; CYTOCHROME P-450 CYP2D6; GENETIC SCREENING; GENOTYPE; GERMANY; HUMANS; MENTAL DISORDERS; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS; PROSPECTIVE STUDIES; RISPERIDONE; SPAIN; UNITED STATES;

EID: 66849100008     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.15     Document Type: Article

References (95)

1. van den Akker-van Marle ME, Gurwitz D, Detmar SB et al.: Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7, 783-792 (2006).
2. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).
3. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
4. Bernard S, Neville KA, Nguyen AT, Flockhart DA: Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications. Oncologist 11, 126-135 (2006).
5. Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P450 2136 ( CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-13 (2005).
6. Kirchheiner J, Nickchen K, Bauer M et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 442-473 (2004).
7. Zanger UM, Raimundo S, Eichelbaum M: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369, 23-37 (2004).
8. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl Acad. Sci. USA 90, 11825-11829 (1993).
9. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M: A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br. J. Clin. Pharmacol. 42, 713-719 (1996).
10. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure, Pharmacogenet. Genomics 17, 93-101 (2007).
11. Dorado P, Caceres MC, Pozo-Guisado E, Wong ML, Licinio J, Llerena A: Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 39, 571-574 (2005).
12. de Leon J: AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev. Mol. Diagn. 6, 277-286 (2006).
13. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS: Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin. Pharmacol. Ther. 72, 76-89 (2002).
14. Gaedigk A, Ndjountche L, Divakaran K et al.: Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin. Pharmacol. Ther. 81, 242-251 (2007).
15. Frank D, Jaehde U, Fuhr U: Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur. J. Clin. Pharmacol. 63, 321-333 (2007).
16. Fuhr U, Jetter A, Kirchheiner J: Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the 'cocktail' approach. Clin. Pharmacol. Ther. 81, 270-283 (2007).
17. de Leon J, Susce MT, Murray-Carmichael E: The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol. Diagn. Ther. 10, 135-151 (2006).
18. Kramer WE, Dukek BA, Bruflat JK et al.: Description of new cytochrome P450 2136 (CYP2D6) alleles resulting from aberrant crossover between CYP2D6 and CYP2D7. Biol. Psychiatry 61, 126S (2007).
19. Mulder H, Heerdink ER, van Iersel EE, Wilmink FW, Egberts AC: Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study. Ann. Pharmacother. 41, 408-413 (2007).
20. Chen S, Chou WH, Blouin RA et al.: The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin. Pharmacol. Ther. 60, 522-534 (1996).
21. Murphy GM Jr, Pollock BG, Kirshner MA et al.: CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression, Neuropsychopharmacology 25, 737-743 (2001).
22. Swen JJ, Wilting I, de Goede AL et al.: Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83, 781-787 (2008).
23. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF: Pharmacogenetics of antidepressant medication intolerance. Am. J. Psychiatry 160, 1830-1835 (2003).
24. Murphy MP, Beaman ME, Clark LS et al.: Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a Phase III clinical trial. Pharmacogenetics 10, 583-590 (2000).
25. Kawanishi C, Lundgren S, Agren H, Bertilsson L: Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur. J. Clin. Pharmacol. 59, 803-807 (2004).
26. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther. Drug Monit. 22, 118-121 (2000).
27. Dahl ML: Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin. Pharmacokinet. 41, 453-470 (2002).
28. Spina E, Ancione M, Di Rosa AE, Meduri M, Caputi AP: Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur. J. Clin. Pharmacol. 42, 347-348 (1992).
29. de Leon J, Armstrong SC, Cozza KL: The dosing of atypical antipsychotics, Psychosomatics 46, 262-273 (2005).
30. Dorado P, Berecz R, Penas-LIedo EM, Caceres MC, Llerena A: Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs. Curr. Drug Targets 7, 1671-1680 (2006).
31. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H: The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int. J. Geriatr. Psychiatry 22, 475-484 (2007).
32. Shekelle P, Maglione M, Bagley S et al.: Comparative effectiveness of off-label use of atypical antipsychotics, Vol. 6. Agency for Health Care Research and Quality, MD, USA (2007).
33. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ: The CYP2D6 poor merabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry 66, 15-27 (2005).
34. Reist C, Mintz J, Albers LJ, Jamal MM, Szabo S, Ozdemir V: Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J. Clin. Psychopharmacol. 27, 46-51 (2007).
35. Pandina. GJ, Aman MG, Findling RL: Risperidone in the management of disruptive behavior disorders. J. Child Adolesc. Psychopharmacol. 16, 379-392 (2006).
36. Cáceres MC: Doctoral Thesis. University of Extremadura, Badajoz, Spain (2006).
37. Bagnall AM, Jones L, Ginnelly L et al.: A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol, Assess. 7, 1-193 (2003).
38. Jayaram MB, Hosalli P: Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst. Rev. CD005237 (2005).
39. Brown K, Levy H, Brenner C, Leffler S, Hamburg EL: Overdose of risperidone. Ann. Emerg. Med. 22, 1908-1910 (1993).
40. Lo Vecchio F, Hamilton RJ, Hoffman RJ: Risperidone overdose. Am. J. Emerg. Med. 14, 95-96 (1996).
41. Kopala LC, Day C, Dillman B, Gardner D: A case of risperidone overdose in early schizophrenia: a review of potential complications. J. Psychiatry Neurosci. 23, 305-308 (1998).
42. Ravin DS, Levenson JW: Fatal cardiac event following initiation of risperidone therapy. Ann. Pharmacother. 31, 867-870 (1997).
43. Zarate CA Jr, Baldessarini RJ, Siegel AJ et al.: Risperidone in the elderly: a pharmacoepidemiologic study. J. Clin. Psychiatry 58, 311-317 (1997).
44. Posey DJ, Walsh KH, Wilson GA, McDougle CJ: Risperidone in the treatment of two very young children with autism. J. Child Adolesc. Psychopharmacol. 9, 273-276 (1999).
45. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151, 825-835 (1994).
46. Lieberman JA, Stroup TS, McEvoy JP et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223 (2005).
47. Heykants J, Huang ML, Mannens G et al.: The pharmacokinetics of risperidone in humans: a summary. J. Clin. Psychiatry 55(Suppl.), 13-17 (1994).
48. Prior TI, Chue PS, Tibbo P, Baker GB: Drug metabolism and atypical antipsychotics. Eur. Neuropsychopharmacol. 9, 301-309 (1999).
49. Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch. Pharmacol. 359, 147-151 (1999).
50. Jung SM, Kim KA, Cho HK et al.: Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin. Pharmacol. Ther. 78, 520-528 (2005).
51. Mahatthanatrakul W, Nontaput T, Ridtitid W, Wongnawa M, Sunbhanich M: Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. J. Clin. Pharm. Ther. 32, 161-167 (2007).
52. Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP: Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther. Drug Monit. 21, 105-115 (1999).
53. Llerena A, Berecz R, Dorado P et al.: Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 783, 213-219 (2003).
54. de Leon J, Bork J: Risperidone and cytochrome P450 3A. J. Clin. Psychiatry 58, 450 (1997).
55. Huang ML, van Peer A, Woestenborghs R et al.: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther. 54, 257-268 (1993).
56. Berecz R, Llerena A, de la Rubia A et al.: Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry 35, 231-234 (2002).
57. Llerena A, Berecz R, Dorado P, de la Rubia A: QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J. Psychopharmacol. 18, 189-193 (2004).
58. de Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ: A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40, 93-102 (2007).
59. Ereshefsky L, Lacombe S: Pharmacological profile of risperidone. Can. J. Psychiatry 38(Suppl. 3), S80-S88 (1993).
60. Schotte A, Bonaventure P, Janssen PF, Leysen JE: In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J. Pharmacol. 69, 399-412 (1995).
61. Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K: Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther. Drug Monit. 20, 380-384 (1998).
62. Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L: Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur. J. Clin. Pharmacol. 57, 671-675 (2001).
63. Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML: Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl.) 147, 300-305 (1999).
64. Troost PW, Lahuis BE, Hermans MH et al.: Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J. Clin. Psychopharmacol. 27, 52-57 (2007).
65. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL: The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol. 7, 415-419 (2004).
66. Bork JA, Rogers T, Wedlund PJ, de Leon J: A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J. Clin. Psychiatry 60, 469-476 (1999).
67. Guzey C, Aamo T, Spigset O: Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer. J. Clin. Psychiatry 61, 600-601 (2000).
68. Kohnke MD, Griese EU, Stosser D, Gaertner I, Barth G: Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 35, 116-118 (2002).
69. Kakihara S, Yoshimura R, Shinkai K et al.: Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int. Clin. Psychopharmacol. 20, 71-78 (2005).
70. Plesnicar BK, Zalar B, Breskvar K, Dolzan V: The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J. Psychopharmacol. 20, 829-833 (2006).
71. Riedel M, Schwarz MJ, Strassnig M et al.: Risperidone plasma levels, clinical response and side-effects. Eur. Arch. Psychiatry Clin. Neurosci. 255, 261-268 (2005).
72. Albrecht A, Morena PG, Baumann P, Eap CB: High dose of depot risperidone in a nonresponder schizophrenic patient. J. Clin. Psychopharmacol. 24, 673-674 (2004).
73. de Leon J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ: Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am. J. Psychiatry 155, 1278-1280 (1998).
74. Chou WH, Yan FX, de Leon J et al.: Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J. Clin. Psychopharmacol. 20, 246-251 (2000).
75. Shabo A: Integrating genomics into clinical practice: standards and regulatory challenges. Curr. Opin. Mol. Ther. 10, 267-272 (2008).
76. Wuttke H, Rau T, Heide R et al.: Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin. Pharmacol. Ther. 72, 429-437 (2002).
77. Bijl M, Visser L, van Schaik R et al.: Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in β-blocker users. Clin. Pharmacol. Ther. 85(1), 45-50 (2008).
78. Rau T, Wuttke H, Michels L et al.: Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin. Pharmacol Ther. 85(3),269-272 (2008).
79. Susce MT, Murray-Carmichael E, de Leon J: Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1356-1358 (2006).
80. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368, 704 (2006).
81. de Leon J, Nikoloff DM: Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. CNS Spectr. 13, 133-135 (2008).
82. Akutsu T, Kobayashi K, Sakurada K, Ikegaya H, Furihata T, Chiba K: Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab. Dispos. 35, 72-78 (2007).
83. Goetz MP, Knox SK, Suman VJ et al.: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113-121 (2007).
84. Goetz MP, Rae JM, Suman VJ et al.: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
85. Schroth W, Antoniadou L, Fritz P et al.: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007).
86. Wegman P, Vainikka L, Stal O et al.: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7, R284-R290 (2005).
87. Kiyotani K, Mushiroda T, Sasa M et al.: Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 99, 995-999(2008).
88. de Leon J, Armstrong SC, Cozza KL: Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47, 75-85 (2006).
89. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116, 496-526 (2007).
90. Cai WM, Nikoloff DM, Pan RM et al.: CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J. 6, 343-350 (2006).
91. Llerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L: Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 87(1), 23-28 (1993).
92. Kirchheiner J, Nickchen K, Sasse J, Bauer M, Roots I, Brockmoller J: A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacagenomics J. 7, 48-55 (2007).
93. Brockmoller J, Kirchheiner J, Schmider J et al.: The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin. Pharmacol. Ther. 72, 438-452 (2002).
94. Llerena A, Dorado P, Peñas-Lledó EM, Cáceres MC, De la Rubia A: Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J. 7(6), 408-410 (2007).
95. de Leon J, Susce MT, Johnson M et al.: DNA microarray technology in the clinical environment: the AmpliChip, CYP 450 Test for CYP2D6 and CYP2C19 genotyping. CNS Spectrums 14, 19-34 (2008).